ClinicalTrials.gg
RecruitingNCT06914583Updated Apr 6, 2025

Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness

An interventional study of Sodium Hyaluronate in Facial Dryness and Facial Dullness, sponsored by IBSA Farmaceutici Italia Srl. Recruiting at 6 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by IBSA Farmaceutici Italia Srl (part of IBSA Institut Biochimique SA) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the safety and efficacy of sodium hyaluronate 32 mg/ml in improving facial skin dryness and dullness. Subjects are randomized to the treatment group or to the control group. Only subjects in the treatment group are treated by intradermal injection.

Read the detailed description

This is a prospective multi-center clinical investigation. Enrolled subjects are randomized to the treatment group or to the no-treatment control group. The treatment group will receive intradermal injections of sodium hyaluronate 32 mg/ml. The improvement of facial skin dryness and dullness will be evaluated at multiple timepoints.

02

Conditions studied

  • Facial Dryness
  • Facial Dullness
03

In context

Lead sponsor

IBSA Farmaceutici Italia Srl is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old and ≤65 years old (based on the time of signing the ICF), gender is not restricted;
  2. Skin Fitzpatrick is classified as type II-IV;
  3. Subjects who are seeking temporary improvement of their dry facial skin and dull complexion. The investigator has assessed the subjects are suitable for receiving injectable treatment to improve these conditions;
  4. Subjects who have agreed not to use any other medical cosmetic treatments related to the study during the study period;
  5. Subjects who voluntarily sign a written form, and able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and subjects able to cooperate with the investigator and to comply with the requirements of the entire investigation (including ability to attend all the planned investigation visits according to the time limits), based on investigator's judgement.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to hyaluronic acid or any component of this product;
  2. Known history of severe allergies;
  3. Known history of severe disease;
  4. Subjects with episode of herpes cutis;
  5. Subjects with cicatricial diathesis;
  6. Facial area has unknown injection substances;
  7. Have received any permanent or semi-permanent fillers at the facial area (e.g., calcium hydroxyapatite, poly-L-lactic acid, polymethyl methacrylate, silicones, expanded polytetrafluoroethylene (ePTFE), polycaprolactone, etc.), autologous fat, face lift (including thread lifts), etc., or plan to receive any of the above treatments during the investigation;
  8. Have received temporary dermal filler treatment (e.g., cross-linked hyaluronic acid, collagen) at the facial area within the 12 months prior to enrolment, or plan to receive any of the above treatments during the investigation;
  9. Have received botulinum toxin injection, mesotherapy, or facial cosmetic procedures (e.g., facial liposuction, cosmetic surgery, face slimming, photo modulation therapy, intense pulsed light, radiofrequency, non-cross-linked hyaluronic acid injection (except for mesotherapy), dermabrasion, laser or chemical peels or other ablation procedures, etc.) at facial area within 6 months prior to enrolment, or plan to receive any of the above treatments during the investigation;
  10. Have received sodium hyaluronate compound solution injection (mesotherapy, etc) at facial area within 3 months prior to enrolment,
  11. Facial area has active or progressive skin infection (including viral, bacterial, fungal);
  12. Facial area has skin granuloma;
  13. Facial area has active or progressive skin diseases or with isomorphic reactions such as acute eczema, flat warts, lichen planus, psoriasis vulgaris, etc.;
  14. Facial area has malignant tumors or skin tumors of unknown nature;
  15. Subjects who work outdoors for a long time or need to be exposed to sunlight after surgery;
  16. Patients with excessive expectations for treatment effects;
  17. Subjects with coagulation dysfunction or other systemic diseases;
  18. Subjects undergoing chemotherapy/radiotherapy;
  19. Subjects with mental illness or emotional instability;
  20. Subjects who had received any thrombolytic agents, anticoagulants or antiplatelet drugs within 2 weeks before enrolment;
  21. Subjects who are pregnant or planned to become pregnant during the investigation period, or breastfeeding;
  22. Subject who participated in other clinical investigation within 1 month prior to enrolment in this investigation, or currently participating in other clinical investigation;
  23. The investigator considers that the subject is not suitable to participate in this clinical investigation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Treatment group

    The treatment group will receive intradermal injections of sodium hyaluronate

    Device: Sodium Hyaluronate

  • No intervention
    Control group

    The control group will not receive any treatment

Interventions

  • DeviceSodium Hyaluronate

    Sodium Hyaluronate 32 mg/ml

06

What researchers measure

Primary outcomes

  1. GAIS (Global Aesthetic Improvement Scale) - Blinded evaluator

    Treatment effective rate (third-party blinded investigator assessment)

    Time frame: 12 week

Secondary outcomes

  1. GAIS-Blinded evaluator

    Treatment effective rate (third-party blinded investigator assessment)

    Time frame: 4week, 8week, 10week, 16week, 20week

  2. GAIS-Investigator

    Treatment effective rate (treating investigator assessment)

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  3. GAIS-Subject

    Treatment effective rate (subject assessment)

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  4. Improvement of skin moisture

    Corneometer assessment

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  5. Skin dryness improvement assessment - Investigator

    Dryness improvement assessment will be performed by the treating investigator. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  6. Skin dryness improvement assessment - Subject

    Dryness improvement assessment will be performed by the subect. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  7. Skin dullness improvement assessment - Investigator

    Skin dullness improvement assessment will be performed by the treating investigator. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  8. Skin dulless improvement - Subject

    Skin dullness improvement assessment will be performed by the subject. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  9. Subject treatment satisfaction assessment scale

    For the question "How do you feel satisfied with the treatment effect of the investigational product?", the answer criteria are from 1 to 5, where 1= very dissatisfied and 5= very much satisfied.

    Time frame: 4week, 8week, 10week, 12week, 16week, 20week

  10. Red blood cell (RBC)

    Time frame: 0week, 12week, 32 week

  11. White blood cell (WBC)

    Time frame: 0week, 12week, 32 week

  12. Platelet count (PLT)

    Time frame: 0week, 12week, 32 week

  13. Hemoglobin (HGB)

    Time frame: 0week, 12week, 32 week

  14. Serum alanine aminotransferase (ALT)

    Time frame: 0week, 12week, 32 week

  15. Serum aspartate aminotransferase (AST)

    Time frame: 0week, 12week, 32 week

  16. Serum urea nitrogen/urea (BUN/Urea)

    Time frame: 0week, 12week, 32 week

  17. Serum creatinin (Cr)

    Time frame: 0week, 12week, 32 week

  18. Blood glucose (GLU)

    Time frame: 0week, 12week, 32 week

  19. Urine pH

    Time frame: 0week, 12week, 32 week

  20. Urine glucose

    Time frame: 0week, 12week, 32 week

  21. Urine protein

    Time frame: 0week, 12week, 32 week

  22. Urine specific gravity

    Time frame: 0week, 12week, 32 week

  23. Urine red blood cell count

    Time frame: 0week, 12week, 32 week

  24. Urine white blood cell count

    Time frame: 0week, 12week, 32 week

  25. Urine nitrite

    Time frame: 0week, 12week, 32 week

  26. Prothrombin time (PT)

    Time frame: 0week

  27. Activated partial thromboplastin time (APTT)

    Time frame: 0week

  28. Thrombin time (TT)

    Time frame: 0week

  29. Fibrinogen (FIB)

    Time frame: 0week

  30. Blood pressure (mmHg)

    Systolic blood pressure and diastolic blood pressure will be measured

    Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week

  31. Temperature (°C)

    Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week

  32. Respiration rate

    Times/min

    Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week

  33. Heart rate

    Beats/min

    Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week

  34. Incidence rate of adverse events (AEs)

    Incidence rate (%) and number of adverse events (AEs)

    Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week

  35. Incidence rate of serious adverse events (SAEs)

    Incidence rate (%) and number of serious adverse events (SAEs)

    Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week

  36. Incidence rate of adverse device effects (ADE)

    Incidence rate (%) and number of adverse device effects (ADE)

    Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week

  37. Incidence rate of serious adverse device effects (SADE)

    Incidence rate (%) and number of serious adverse device effects (SADE)

    Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week

  38. Incidence rate of injection site reactions

    Incidence rate (%) and number of injection site reactions

    Time frame: 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week

  39. Incidence rate of device deficiencies

    Incidence rate (%) and number of of device deficiencies

    Time frame: 0week, 4week, 8week

07

Study locations

4 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Nov 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 6, 2025
StartActual
Feb 19, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Feb 2026
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06914583
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Feb 19, 2025
Primary completion
Nov 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Apr 6, 2025

Study contacts

Yan Wu, Professor
Contact
3437477565@qq.com
13910978643

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion